Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin

Introduction Several prostate cancers carry homologous recombination repair mutations that respond to olaparib. Because of the mechanism, the efficacy of platinum‐based therapy can be used to predict the efficacy of poly(adenosine diphosphate‐ribose) polymerase inhibitors such as olaparib. Case pres...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Yoshiyuki Miyazawa, Takanori Shimizu, Yoshitaka Sekine, Seiji Arai, Akira Ohtsu, Yuji Fujizuka, Masashi Nomura, Hidekazu Koike, Hiroshi Matsui, Kazuhiro Suzuki
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Wiley 2023-01-01
Saila:IJU Case Reports
Gaiak:
prostate cancer
castration‐resistant prostate cancer
neuroendocrine prostate cancer
poly(adenosine diphosphate‐ribose) polymerase
BRCA
Sarrera elektronikoa:https://doi.org/10.1002/iju5.12543

Internet

https://doi.org/10.1002/iju5.12543

Antzeko izenburuak